Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incannex Healthcare Inc IXHL

Healthcare
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety... see more

Recent & Breaking News (NDAQ:IXHL)

Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

GlobeNewswire July 21, 2023

Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea

GlobeNewswire July 18, 2023

Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

GlobeNewswire July 13, 2023

Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq

GlobeNewswire July 10, 2023

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company's Proprietary Drug for Treatment of Obstructive Sleep Apnoea ('OSA')

GlobeNewswire July 6, 2023

Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023

GlobeNewswire June 23, 2023

Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

GlobeNewswire June 16, 2023

World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board

GlobeNewswire May 30, 2023

Incannex Company Presentation - Presentation of Psychennex, Psychedelic Therapies Subsidiary Company

GlobeNewswire May 16, 2023

Incannex enters a lease for first psychedelic-assisted psychotherapy clinic

GlobeNewswire May 5, 2023

Incannex Company Presentation - Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

GlobeNewswire May 3, 2023

Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A

GlobeNewswire May 2, 2023

Incannex Appoints QPS to Advance CannQuit-N(TM) (Nicotine), CannQuit-O(TM) (Opioid) and Renecann(TM) Products in the USA and EU

GlobeNewswire April 14, 2023

Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts

GlobeNewswire March 16, 2023

Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment

GlobeNewswire March 15, 2023

Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use

GlobeNewswire March 3, 2023

Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

GlobeNewswire February 28, 2023

Independent data review commences for Phase 2 trial of psilocybin-assisted psychotherapy for anxiety

GlobeNewswire January 18, 2023

Incannex Expands Intellectual Property Position over IHL-42X

GlobeNewswire December 6, 2022

Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases

GlobeNewswire November 29, 2022